Effect of statin on risk of gynecologic cancers: A meta-analysis of observational studies and randomized controlled trials

Liu, Yanqiong; Qin, Aiping; Li, Taijie; Qin, Xue; Li, Shan

doi:10.1016/j.ygyno.2014.04.007

Cited by 58 publications

(58 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, in a meta-analysis of the effect of statin use on risk of gynecologic cancers, there was no association of decreased incidence of endometrial cancers found for statin users. 25 However, in this meta-analysis, there was no distinction made between histopathologic subtypes of endometrial cancers. Studies confined to Unauthorized reproduction of this article is prohibited.…”

Section: Discussionmentioning

confidence: 76%

Association Between Statin Use and Endometrial Cancer Survival

Nevadunsky

Arsdale

Strickler

et al. 2015

Obstetrics & Gynecology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 76%

Association Between Statin Use and Endometrial Cancer Survival

Nevadunsky

Arsdale

Strickler

et al. 2015

Obstetrics & Gynecology

View full text Add to dashboard Cite

show abstract

“…However, there were only 320 women with high-grade serous carcinoma enrolled in this study who were on statins. Contrarily, a recent meta-analysis of fourteen studies that included cohort, case-control, and randomized controlled trials, statin use was associated with a 21% reduction in ovarian cancer risk and there was no significant heterogeneity among studies (13). To date, only two observational studies (with 150 cases or fewer) have been published that examined the association between statin use and ovarian cancer mortality (14)(15).…”

Section: Introductionmentioning

confidence: 99%

Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models

Kobayashi

Kashima

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose Statins are among the most frequently prescribed drugs because of their efficacy and low toxicity in treating hypercholesterolemia. Recently, statins have been reported to inhibit the proliferative activity of cancer cells, especially those with TP53 mutations. Since TP53 mutations occur in almost all of the ovarian high-grade serous carcinoma, we determined if statins suppressed tumor growth in animal models of ovarian cancer. Experimental Design Two ovarian cancer mouse models were employed. The first one was a genetically engineered model, mogp-TAg, in which the promoter of oviduct glycoprotein-1 was used to drive the expression of SV40 T-antigen in gynecologic tissues. These mice spontaneously develop serous tubal intraepithelial carcinomas (STICs), which are known as ovarian cancer precursor lesions. The second model was a xenograft tumor model in which human ovarian cancer cells were inoculated into immunocompromised mice. Mice in both models were treated with lovastatin, and effects on tumor growth were monitored. The molecular mechanisms underlying the anti-tumor effects of lovastatin were also investigated. Results Lovastatin significantly reduced the development of STICs in mogp-TAg mice and inhibited ovarian tumor growth in the mouse xenograft model. Knockdown of prenylation enzymes in the mevalonate pathway recapitulated the lovastatin-induced anti-proliferative phenotype. Transcriptome analysis indicated that lovastatin affected the expression of genes associated with DNA replication, Rho/PLC signaling, glycolysis, and cholesterol biosynthesis pathways, suggesting that statins have pleiotropic effects on tumor cells. Conclusion The above results suggest that repurposing statin drugs for ovarian cancer may provide a promising strategy to prevent and manage this devastating disease.

show abstract

“…Although a Danish case-control study showed no impact of statin use on ovarian cancer risk, a meta-analysis demonstrated a decrease risk of ovarian cancer with long term use (>5 years) (RR 0.49; 95% CI 0.28-0.80)(137, 138). Preclinical evidence for a possible use of statins as chemoprevention for high risk patients includes a decrease in STIC formation among mogp-TAg mice with lovastatin administration(139).…”

Section: Medical Prevention For Women At High Risk Of Ovarian Cancermentioning

confidence: 98%

Ovarian Cancer Prevention in High-risk Women

Temkin

Bergstrom²,

Samimi

et al. 2017

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Ovarian carcinoma is the most lethal malignancy of the female genital tract. Population-based trials in the general population have not demonstrated that screening improves early detection or survival. Therefore, application of prevention strategies is vital to improving outcomes from this disease. Surgical prevention reduces risk and prophylactic risk reducing salpingo-oophorectomy (RRSO) is the most effective means to prevent ovarian carcinoma in the high risk patient although the risks do not outweigh the benefits in average risk patients. Other surgical and medical options have unknown or limited efficacy in the high risk patient. In this review, we define the patient at high risk for ovarian cancer, discuss how to identify these women and weigh their available ovarian cancer prevention strategies.

show abstract

Effect of statin on risk of gynecologic cancers: A meta-analysis of observational studies and randomized controlled trials

Cited by 58 publications

References 42 publications

Association Between Statin Use and Endometrial Cancer Survival

Association Between Statin Use and Endometrial Cancer Survival

Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models

Ovarian Cancer Prevention in High-risk Women

Contact Info

Product

Resources

About